Carol Crouch-Ross, MD
Child & Adolescent Psychiatry · Livonia, MINPI 1053466946
Payments from drug & device makers
Across 972 payments — averaging $25.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$5K
- Lundbeck LLC$3K
- Takeda Pharmaceuticals U.S.A., Inc.$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$3K
- AbbVie$2K
- Teva Pharmaceuticals USA, Inc.$1K
- plus $7K from 22 others
What the payments were for
- Food & beverage$24,350100%
- Education$380%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 126 | $4,523 |
| Lundbeck LLC | 165 | $3,317 |
| Takeda Pharmaceuticals U.S.A., Inc. | 167 | $3,080 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 89 | $2,584 |
| AbbVie(2 entities) | 114 | $2,175 |
| Teva Pharmaceuticals USA, Inc. | 57 | $1,463 |
| Axsome Therapeutics, Inc. | 20 | $943 |
| Corium, LLC | 32 | $809 |
| Neurocrine Biosciences, Inc. | 23 | $774 |
| Supernus Pharmaceuticals, Inc. | 45 | $741 |
| E.r. Squibb & Sons, L.L.C. | 16 | $720 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 8 | $649 |
| Ironshore Pharmaceuticals Inc. | 10 | $382 |
| Tris Pharma Inc | 16 | $367 |
| Alkermes, Inc. | 11 | $283 |
| Shire North American Group Inc | 14 | $272 |
| Johnson & Johnson | 9 | $259 |
| Eisai Inc. | 6 | $216 |
| Neos Therapeutics, LP | 14 | $208 |
| Adlon Therapeutics L.p. | 8 | $175 |
| Idorsia Pharmaceuticals US Inc | 6 | $123 |
| Avanir Pharmaceuticals, Inc. | 5 | $96 |
| Jazz Pharmaceuticals Inc. | 3 | $58 |
| Sunovion Pharmaceuticals Inc. | 1 | $50 |
| Arbor Pharmaceuticals, Inc. | 3 | $47 |
| Validus Pharmaceuticals LLC | 2 | $35 |
| Livanova USA, Inc. | 1 | $23 |
| Noven Therapeutics, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$2,827
- CAPLYTA$685
- Auvelity$585
- VRAYLAR$495
- LYBALVI$409
- Austedo XR$249
- INGREZZA$245
- Azstarys$242
- Jornay PM 20mg capsules (Bottle of 100)$236
- QELBREE$125
- TRINTELLIX$121
- SPRAVATO$121
- COBENFY$120
- Dayvigo$108
- Dyanavel XR$107
How this compares
$24,387 in reported general payments places this provider in the 95th percentile of 73 child & adolescent psychiatry providers in Michigan.
See all child & adolescent psychiatry providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 25 | $44,633 |
| VraylarCariprazine Hcl | 13 | $18,999 |
| Aripiprazole | 70 | $7,340 |
| TrintellixVortioxetine Hydrobromide | 11 | $5,052 |
| Trazodone Hcl | 121 | $2,975 |
| Duloxetine Hcl | 113 | $1,865 |
| Trifluoperazine Hcl | 12 | $1,856 |
| Bupropion XlBupropion Hcl | 88 | $1,647 |
| Alprazolam | 167 | $1,543 |
| Divalproex Sodium ErDivalproex Sodium | 29 | $1,478 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 30 | $1,287 |
| Atomoxetine Hcl | 12 | $1,263 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 63 | $1,171 |
| Amphetamine Sulfate | 12 | $1,094 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 21 | $907 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $4,523 | $44,63325 claims |
| AbbVieVraylar | $2,175 | $18,99913 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $3,080 | $5,05211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 73 child & adolescent psychiatry providers in Michigan.
Other child & adolescent psychiatry in Livonia
- Sridevi KodaliLivonia$7K
- Birgit AmannTroy$980K
- David VillanuevaSterling Heights$140K
- Jeffrey LondonTroy$28K
- Robert GarciaNorthville$24K
- Mohammad JafferanySaginaw$17K
- Gerald SchmukerSpring Lake$11K
- Viken MatossianHowell$5K
- Seema KumarWest Bloomfield$4K
- Davinder KakarBloomfield Hills$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.